ANVISA guidelines for two-stage design [Two-Stage / GS Designs]

posted by Mauricio Sampaio  – Brazil, 2020-02-12 18:11 (1090 d 21:36 ago) – Posting: # 21167
Views: 5,122

Hi El Maestro

❝ Ermmm...... WHAT???? :-D:party:


Sorry! Change to: unknowledgement of intra-individual variability.

Now, any comments or contribution?

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
14 visitors (0 registered, 14 guests [including 6 identified bots]).
Forum time: 15:48 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5